Immutep Limited Faces Class Action Amid TACTI-004 Trial Controversy and Investor Losses

In a significant development for investors in Immutep Limited (NASDAQ: IMMP), a securities class action has been initiated, signaling a growing concern among shareholders regarding the company's internal disclosures and trial results. This lawsuit follows a dramatic collapse in the value of Immutep's ADRs, which plummeted approximately 83% in a single trading session after revelations pertaining to the TACTI-004 trial.

The Context of Investor Losses

Investors who purchased Immutep ADRs between March 24, 2025, and March 12, 2026, may find themselves adversely affected by these recent developments. In particular, those who have seen their investments decrease sharply are encouraged to submit their information to seek recovery of their losses. The lawsuit highlights grave misstatements concerning the efficacy and safety of the TACTI-004 Phase III trial, which the company allegedly misrepresented over an extended period.

On March 13, 2026, Immutep announced the discontinuation of the TACTI-004 trial due to its inability to meet primary efficacy or safety endpoints, revealing that internal data had pointed to potential failures in the trial. This disclosure came after months of optimistic projections from the company's management, painting a positive picture of the trial's progress despite the internal knowledge of escalating risks.

Allegations of Concealment

The class action contends that Immutep's executives possessed critical internal data suggesting that the TACTI-004 trial was unlikely to succeed. Despite this sensitive information, communications with the public portrayed a consistently positive outlook regarding the trial's advancements. Management continuously emphasized